REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2017

Aug 25, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-08-23

Reporting Person: Sanofi (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-23	Common Stock	P	1900	$475.9732	Acquired	23643644	Indirect
2017-08-23	Common Stock	P	9600	$477.3484	Acquired	23653244	Indirect
2017-08-23	Common Stock	P	12186	$478.3422	Acquired	23665430	Indirect
2017-08-23	Common Stock	P	23872	$479.451	Acquired	23689302	Indirect
2017-08-23	Common Stock	P	13037	$480.3731	Acquired	23702339	Indirect
2017-08-24	Common Stock	P	2633	$474.8578	Acquired	23704972	Indirect
2017-08-24	Common Stock	P	5103	$475.9319	Acquired	23710075	Indirect
2017-08-24	Common Stock	P	10929	$477.4224	Acquired	23721004	Indirect
2017-08-24	Common Stock	P	3326	$478.1171	Acquired	23724330	Indirect
2017-08-24	Common Stock	P	8273	$479.2349	Acquired	23732603	Indirect
2017-08-24	Common Stock	P	13638	$480.3643	Acquired	23746241	Indirect
2017-08-24	Common Stock	P	17756	$481.3267	Acquired	23763997	Indirect
2017-08-24	Common Stock	P	1700	$481.9565	Acquired	23765697	Indirect
2017-08-24	Common Stock	P	5016	$483.3125	Acquired	23770713	Indirect
2017-08-24	Common Stock	P	8982	$484.2671	Acquired	23779695	Indirect
2017-08-24	Common Stock	P	5724	$485.5536	Acquired	23785419	Indirect
2017-08-24	Common Stock	P	6920	$486.6264	Acquired	23792339	Indirect
2017-08-24	Common Stock	P	8860	$487.5532	Acquired	23801199	Indirect
2017-08-24	Common Stock	P	6960	$488.574	Acquired	23808159	Indirect

Footnotes

F1: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").

F3: Purchase prices range from $475.51 to $476.50 per share, inclusive.

F4: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC ("Aventis"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.

F5: Purchase prices range from $476.78 to $477.75 per share, inclusive.

F6: Purchase prices range from $477.81 to $478.80 per share, inclusive.

F7: Purchase prices range from $478.89 to $479.87 per share, inclusive.

F8: Purchase prices range from $479.91 to $480.86 per share, inclusive.

F9: Purchase prices range from $474.40 to $475.21 per share, inclusive.

F10: Purchase prices range from $475.55 to $476.43 per share, inclusive.

F11: Purchase prices range from $476.79 to $477.78 per share, inclusive.

F12: Purchase prices range from $477.79 to $478.76 per share, inclusive.

F13: Purchase prices range from $478.79 to $479.70 per share, inclusive.

F14: Purchase prices range from $479.80 to $480.77 per share, inclusive.

F15: Purchase prices range from $480.82 to $481.80 per share, inclusive.

F16: Purchase prices range from $481.89 to $482.59 per share, inclusive.

F17: Purchase prices range from $482.91 to $483.90 per share, inclusive.

F18: Purchase prices range from $483.93 to $484.74 per share, inclusive.

F19: Purchase prices range from $485.00 to $485.98 per share, inclusive.

F20: Purchase prices range from $486.01 to $486.95 per share, inclusive.

F21: Purchase prices range from $487.02 to $488.01 per share, inclusive.

F22: Purchase prices range from $488.04 to $488.82 per share, inclusive.